Navigation Links
Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
Date:9/24/2008

FDA Expert on Pharmacogenomics Offers a Prescription for Progress

WATERBURY, Conn., Sept. 24 /PRNewswire/ -- The Connecticut State Medical Society is joining with Genomas(R), a biomedical company advancing DNA-guided medicine and personalized healthcare, to co-sponsor a symposium -- DNA-Guided Medicine and the Path to Personalized Health Care -- being held today at the Society's annual meeting. Hartford Hospital is providing continuing medical education credits for physicians attending the meeting.

Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, will discuss FDA Initiatives in Personalized Medicine: Advancing Individualized Drug Therapy.

Dr Lesko commented: "The U.S. Department of Health and Human Services and the FDA have prioritized personalized medicine as one of their mission goals for public health. I am glad to participate in this event with the Connecticut Medical Society, Hartford Hospital and Genomas to bring these initiatives to physicians who are in an important position to implement them in their clinical practice. Connecticut is poised to become one of the national leaders in adoption of personalized medicine, and I am thrilled to join ranks with these local efforts as exemplary to improving the healthcare system as a whole."

Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, will speak about Progress Towards DNA-Guided Medicine in Clinical Practice: Case Studies in Cardiology and Psychiatry. Examples in these two therapeutic areas include statins and atypical antipsychotics.

Dr. Ruano commented: "We are privileged to partner with the Connecticut State Medical Society to convene the physicians in our state for this forum. The presence of the FDA is an indication of the national impact of the programs in DNA-Guided Medicine that Genomas has spearheaded in Connecticut with Hartford Hospital and the Hospital of Central Connecticut. Together, we are bringing personalized healthcare to our patients today, and setting the pathway to utilization of DNA-Guided Medicine as the standard of care in cardiovascular and psychiatric clinical practice."

ABOUT GENOMAS

Genomas Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with the unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information, please visit http://www.genomas.net

ABOUT PHYZIOTYPE CLINICAL MANAGEMENT SYSTEMS

PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a biomathematical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. To date, Genomas has secured $3.1 million from NIH Small Business Innovation Research (SBIR) for PhyzioType System product development.


'/>"/>
SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Connecticut Technology Council to Recognize Fast Growing Technology Companies
2. Connecticut BioBus Travels to State Capitol on April 24 for Tours and Experiments with Visiting Students
3. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
4. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
5. NC State engineers discover nanoparticles can break on through
6. Department of Justice Provides States With Funding for Testing in Postconviction Cases
7. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
8. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
9. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
10. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
11. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 that ... test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for ... NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/26/2017)... 2017  Genisphere LLC, provider of the 3DNA ... collaborative and sponsored research agreement with the University ... The overall goal of the partnership is to ... designs and formulations after in vivo ... vasculature as well as inflammatory responses, demonstrating various ...
(Date:4/25/2017)... 2017 Providence -based ... novel immune-modulating technology to an undisclosed global pharmaceutical company, ... Tregitopes, pronounced TĀ·rejĀ·itopes, are a set of ... CEO Annie De Groot and EpiVax ... an autoimmune disease therapy, Tregitopes are capable of ...
(Date:4/24/2017)... Yorba Linda, Ca (PRWEB) , ... April 24, ... ... can protect proteins from thermal denaturation in a cellular milieu; however, the broad ... by a lack of simple platforms with sensitive quantitative readouts. Cell-based thermal stabilization ...
Breaking Biology Technology:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
Breaking Biology News(10 mins):